APTO News and Press, Aptose Biosciences Inc. From 06/11/21

Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%,&...

coffeekai/iStock via Getty Images Aptose Biosciences (APTO) has lost ~24.5% in early hours after the company announced updates on its clinical program for luxeptinib currently undergoing two Phase 1 a/b trials in blood cancers. The oral, first-in-class FLT3 and BTK kinase ...

Orphazyme (ORPH) -49% Orphazyme stock losing half its value premarket, after rocketing fourfold the day beforeCVR Energy (CVI) -18%.Curis (CRIS) -13% on updated data for CA-4948 in blood cancers.Galecto (GLTO) -16%.Aptose Biosciences (APTO) -15% presents highlights from EH...

SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is relea...

APTO is presenting new data at EHA21 for its Btk inhibitor, Luxeptinib. The data could be a catalyst event (up or down) for this stock. There's a lot of competition for non-covalent Btk inhibitors in blood cancers. For further details see: Aptose: Cancer Trial Catalyst A...

Penny Stocks To Watch For June Trading penny stocks is something that millions of people do daily. But it’s isn’t something that everyone has been able to master. Best-known for their high-flying moves in price, the “land of cheap stocks” is more frequently c...

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual Congress SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...

SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate ...

Aptose Biosciences Inc. (APTO) Q1 2021 Earnings Conference Call May 4, 2021 4:30 p.m. ET Company Participants Susan Pietropaolo - Communications Representative William Rice - Chairman, President, and CEO Jotin Marango - SVP, CFO, and Chief Business Officer Rafael Bejar - SVP and Chief Medical...

- Conference call and webcast at 4:30 pm EDT today - - Luxeptinib Phase 1 a/b studies in AML and B cell malignancies continue dose escalation - - APTO-253 Phase 1 a/b study in AML / MDS advances to sixth (210 mg/m 2 ) dose cohort - - Dr. J...